Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genentech licenses gene discovery technology from Genizon
Financial terms were not disclosed, but the companies revealed that, under the terms of the agreement, Genizon will receive an upfront payment, research funding and milestone payments for
Financial terms were not disclosed, but the companies revealed that, under the terms of the agreement, Genizon will receive an upfront payment, research funding and milestone payments for
Zolpidem is the active ingredient found in the number one selling hypnotic, Ambien (zolpidem tartrate), which is marketed by Sanofi-Aventis. The trial, which is being conducted in healthy
AE37 is a novel immunotherapeutic vaccine being developed by Generex’ wholly owned subsidiary Antigen Express. The compound has been in clinical trials for more than a year at
The phase III trial will evaluate approximately 300 previously-treated patients with locally advanced and/or metastatic pancreatic cancer who receive best supportive care (BSC) or glufosfamide once every three
Maryland-based In Vitro Technologies (IVT) supplies products and services to improve the drug discovery and development process. The company’s product portfolio includes proprietary ADME-Tox products, including fresh and
While the terms of the license have not been disclosed, Potentia has announced that this agreement will allow the company to move forward with the preclinical development of
Halozyme’s Enhanze Technology is based on recombinant human PH20 hyaluronidase (rHuPH20). This current clinical trial is designed to compare the pharmacokinetics, safety and tolerability of a large molecule
The Montreal-based company reported in July that a death had occurred in the trial at a clinical site in Argentina. The trial was an international multi-center, randomized, placebo-controlled,
The recommendation is based on preliminary encouraging confirmed and unconfirmed complete response (CR/uCR) rates observed among the first 40 patients with aggressive non-Hodgkin’s lymphoma (NHL) treated in the
The results of the study indicated that 75% of tested mice injected with 5mg of QR-433 were protected from cachexia and did not exhibit any significant weight loss,